Techniques and Innovations in Gastrointestinal Endoscopy最新文献

{"title":"Sequential Endoscopic Antireflux Mucosectomy–Repeat Antireflux Mucosal Ablation Approach: A New Paradigm in Managing Refractory Gastroesophageal Reflux Disease Symptoms?","authors":"Tomasz Klimczak ,&nbsp;Wojciech Ciesielski ,&nbsp;Bartłomiej Gostyński ,&nbsp;Mar Ríos Gutiérrez ,&nbsp;Anton Osnytskyy ,&nbsp;Dominik Przychodniak ,&nbsp;Alina Yanushkevich ,&nbsp;Adam Durczyński ,&nbsp;Janusz Strzelczyk ,&nbsp;Piotr Hogendorf","doi":"10.1016/j.tige.2025.250955","DOIUrl":"10.1016/j.tige.2025.250955","url":null,"abstract":"<div><h3>BACKGROUND AND AIMS</h3><div>Managing proton pump inhibitor (PPI)–resistant gastroesophageal reflux disease (GERD) remains challenging, with limited nonsurgical treatment options. A sequential approach using antireflux mucosectomy (ARMS) followed by repeat antireflux mucosal ablation (reARMA) has emerged as a promising strategy for patients unresponsive to initial intervention.</div></div><div><h3>METHODS</h3><div>We conducted a retrospective study of 36 patients with PPI-refractory GERD who underwent endoscopic ARMS. Patients with persistent symptoms after ARMS were considered for reARMA. Symptom severity was assessed using the Frequency Scale for the Symptoms of GERD, GERD-Health Related Quality of Life scores, acid exposure time, and DeMeester scores.</div></div><div><h3>RESULTS</h3><div>ARMS alone achieved clinical success in 25 patients (69%), with significant reductions in symptom scores, including the Frequency Scale for the Symptoms of GERD (mean reduction from 14 to 6.17; <em>P</em> &lt; 0.001) and GERD-Health Related Quality of Life (<em>P</em> &lt; 0.001). Among 11 patients with persistent symptoms, reARMA led to therapeutic success in 8 cases (73%), with similar significant improvements in all assessed metrics (<em>P</em> &lt; 0.001). No major perioperative or postoperative complications were observed.</div></div><div><h3>CONCLUSION</h3><div>The sequential ARMS-reARMA protocol offers a minimally invasive and effective strategy for managing PPI-resistant GERD. reARMA serves as a valuable second-line endoscopic option, potentially reducing the need for surgical intervention. Further studies are warranted to validate these findings, optimize patient selection, and assess long-term outcomes.</div></div>","PeriodicalId":36169,"journal":{"name":"Techniques and Innovations in Gastrointestinal Endoscopy","volume":"28 2","pages":"Article 250955"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145978971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Needle-Knife Fistulotomy Reduces Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis—A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Fazia Khattak ,&nbsp;Debvarsha Mandal ,&nbsp;Ashesh Das ,&nbsp;Shriya D. Tayade ,&nbsp;Sailesh I.S. Kumar ,&nbsp;Sumaiya Mehveen ,&nbsp;Ritwik Roy ,&nbsp;Krupa Patel ,&nbsp;Umair Hayat ,&nbsp;Emma M. Sam","doi":"10.1016/j.tige.2025.250954","DOIUrl":"10.1016/j.tige.2025.250954","url":null,"abstract":"<div><h3>BACKGROUND AND AIMS</h3><div>Selective biliary cannulation is one of the most crucial steps in endoscopic retrograde cholangiopancreatography (ERCP), and the standard transpapillary cannulation (STC) technique carries a risk of post-ERCP pancreatitis (PEP). Primary needle-knife fistulotomy (PNF) has been recently shown as a safer alternative technique to reduce PEP by avoiding papillary trauma to the pancreatic orifice. A prior meta-analysis suggested a trend toward lower PEP incidence with PNF without a significant difference in overall cannulation success. This systematic review and meta-analysis, including only randomized controlled trials, incorporates recent data to show the efficacy and safety of PNF compared with STC.</div></div><div><h3>METHODS</h3><div>A systematic search of PubMed, Embase, Scopus, and the Cochrane Library identified randomized controlled trials comparing PNF with STC for ERCP through March 2025. Data were analyzed using Review Manager 5.4. Pooled risk ratios (RRs) with 95% CIs were calculated using the Mantel-Haenszel test. Fixed- or random-effects models were used based on heterogeneity (I²). Statistical significance was set at <em>P</em> &lt; 0.05. Risk of bias was assessed using the Cochrane risk of bias tool 2.0. This review is registered with the International Prospective Register of Systematic Reviews (CRD420251051410).</div></div><div><h3>RESULTS</h3><div>PNF was associated with a significantly lower risk of PEP compared with standard cannulation (RR, 0.30; 95% CI, 0.14-0.63; absolute risk difference, 4.5%; 95% CI, 2.0%-7.0%; number needed to treat = 23). This corresponded to a 70% relative risk reduction in pancreatitis with PNF as the initial technique and minimal I² (I² = 10%). Biliary cannulation success rates were comparable (risk difference, 0.07; 95% CI, −0.01 to 0.15; <em>P</em> = 0.09) with substantial I² (I² = 77%). Rates of procedure-related complications, such as cholangitis, bleeding, and perforation, were not significantly different (RR, 1.01; 95% CI, 0.41-2.51; <em>P</em> = 0.98).</div></div><div><h3>CONCLUSION</h3><div>This meta-analysis provides robust evidence that PNF significantly reduces the risk of PEP compared with standard cannulation without increasing the risk of other adverse events.</div></div>","PeriodicalId":36169,"journal":{"name":"Techniques and Innovations in Gastrointestinal Endoscopy","volume":"28 1","pages":"Article 250954"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145796648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide Analysis of Right-Sided Colonic Stenting: Rarely Used but Reduces Stoma Creation Significantly","authors":"Khalid Ahmed ,&nbsp;Ahmed Dirweesh ,&nbsp;Zachary D. Leslie ,&nbsp;Yasmin Ali ,&nbsp;Nabeel Azeem ,&nbsp;Eric Wise ,&nbsp;Cyrus Jahansouz ,&nbsp;Martin Freeman ,&nbsp;Stuart K. Amateau","doi":"10.1016/j.tige.2025.250952","DOIUrl":"10.1016/j.tige.2025.250952","url":null,"abstract":"<div><h3>BACKGROUND AND AIMS</h3><div>Right-sided malignant colonic obstruction frequently requires emergent intervention and is associated with high perioperative morbidity and mortality. Self-expanding metallic stents (SEMSs) have been extensively studied in left-sided disease, but their role in right-sided obstruction remains poorly defined. Our aim was to evaluate nationwide trends, patient characteristics, and outcomes associated with SEMS use in right-sided malignant colonic obstruction.</div></div><div><h3>METHODS</h3><div>Using the Nationwide Readmissions Database (2016-2022), we identified patients with right-sided malignant colonic obstruction. Patients were stratified by SEMS placement. Weighted univariate and multivariable logistic regression analyses were used to compare demographics, hospital characteristics, and 90-day postoperative outcomes.</div></div><div><h3>RESULTS</h3><div>Among 24,146 patients, only 251 (1.0%) underwent SEMS placement. SEMS-treated patients were more likely to be in-state residents (95.0% vs 89.6%), from large metropolitan areas (70.5% vs 53.4%), and from higher-income quartiles (31.0% vs 22.3%; all <em>P</em> &lt; 0.01). SEMS placement was associated with significantly lower stoma rates (&lt;4.0% vs 9.1%; <em>P</em> &lt; 0.01) and higher rates of deep vein thrombosis (8.0% vs 3.8%; <em>P</em> &lt; 0.01). Multivariable analysis showed that SEMS reduced need for stoma (adjusted odds ratio, 0.19; 95% CI, 0.07-0.50), while metastatic disease increased stoma risk (adjusted odds ratio, 2.36; 95% CI, 2.12-2.63).</div></div><div><h3>CONCLUSIONS</h3><div>SEMS use in right-sided malignant obstruction was associated with a significantly lower need for stoma formation and comparable short-term outcomes. Despite potential benefits, utilization remains low. Further prospective studies are warranted to better define patient selection criteria and long-term oncologic outcomes.</div></div>","PeriodicalId":36169,"journal":{"name":"Techniques and Innovations in Gastrointestinal Endoscopy","volume":"28 1","pages":"Article 250952"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145526516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Transoral Incisionless Fundoplication for Post–Esophageal Peroral Endoscopic Myotomy Gastroesophageal Reflux Disease With Esophagitis: A Meta-Analysis","authors":"Yusuf Kagzi,&nbsp;Abuzar Asif,&nbsp;Srinivas Reddy Puli","doi":"10.1016/j.tige.2025.250953","DOIUrl":"10.1016/j.tige.2025.250953","url":null,"abstract":"<div><h3>BACKGROUND AND AIMS</h3><div>Esophageal peroral endoscopic myotomy (E-POEM) is a gold-standard, minimally invasive treatment for achalasia and related esophageal motility disorders. However, gastroesophageal reflux disease (GERD) is a common complication after E-POEM, potentially compromising patient outcome. Transoral incisionless fundoplication (TIF) is an endoscopic technique designed to restore the competency of the gastroesophageal junction and reduce GERD symptoms. This meta-analysis evaluates the safety and efficacy of TIF in managing GERD with esophagitis following E-POEM.</div></div><div><h3>METHODS</h3><div>We performed a comprehensive, systematic search of multiple electronic databases, including conference proceedings, from inception through November 2024 to identify studies that evaluated the efficacy and safety of TIF in patients with GERD post E-POEM. Pooled proportions were calculated using both Mantel-Haenszel method (fixed effects model) and Der Simonian Laird method (random effects model). The heterogeneity among studies was tested using Cochran's Q test based on inverse variance weights. Primary outcomes were technical success, reduction in daily proton-pump inhibitor (PPI) and improvement in esophagitis. Secondary outcomes included procedure time, adverse event rates, and improvement in the GERD Health-Related Quality of Life (GERD-HRQL) Questionnaire.</div></div><div><h3>Results</h3><div>Seven studies comprising 212 patients with post-E-POEM GERD with esophagitis were included, with 59 undergoing TIF. Pooled mean interval between E-POEM and TIF was 16 months (95% CI, 8.00-24.00). Pooled technical success was 100% (95% CI, 91.07-100). GERD Health-Related Quality of Life scores improved from 39.82 ± 11.18 to 14.61 ± 4.6 post-TIF. The pooled odds ratio for esophagitis post-TIF vs pre-TIF was 0.28 (95% CI, 0.10-0.79). Proton pump inhibitor discontinuation was achieved in 69.45% (95% CI, 55.44-81.83). Mean procedure time was 60.17 minutes, and the adverse event rate was 13.87%, with all events being mild, self-limited, and no mortality was reported.</div></div><div><h3>CONCLUSION</h3><div>TIF is a safe and effective treatment for GERD with esophagitis following E-POEM, improving symptoms and reducing proton pump inhibitor dependence. Additional studies are needed to confirm long-term benefits.</div></div>","PeriodicalId":36169,"journal":{"name":"Techniques and Innovations in Gastrointestinal Endoscopy","volume":"28 1","pages":"Article 250953"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Ultrasound–Guided Radiofrequency Ablation for Nonfunctioning Pancreatic Neuroendocrine Tumors","authors":"Prahan Chetlur ,&nbsp;Daniel Marino ,&nbsp;John M. DeWitt ,&nbsp;Patrick Joseph Magahis ,&nbsp;SriHari Mahadev ,&nbsp;Reem Sharaiha ,&nbsp;John Lee ,&nbsp;Jason Samarasena ,&nbsp;Amirali Tavangar ,&nbsp;Frances Dang ,&nbsp;Stefano Francesco Crinò ,&nbsp;Kavel Visrodia ,&nbsp;Amrita Sethi ,&nbsp;John Doyle ,&nbsp;Nirav Thosani ,&nbsp;Gregory Haber ,&nbsp;Lauren Khanna ,&nbsp;Tamas Gonda","doi":"10.1016/j.tige.2026.250971","DOIUrl":"10.1016/j.tige.2026.250971","url":null,"abstract":"<div><h3>BACKGROUNDS AND AIMS</h3><div>Endoscopic ultrasound–guided radiofrequency ablation (EUS-RFA) is a minimally invasive treatment option for nonfunctional pancreatic neuroendocrine tumors (NF-PanNETs). This study aimed to evaluate the efficacy, safety, and predictors of response to EUS-RFA.</div></div><div><h3>METHODS</h3><div>We conducted a retrospective, multicenter case series across 7 tertiary care centers, including 46 patients with biopsy-proven NF-PanNETs. Demographic, tumor, and procedural data were collected. Technical success was defined as completion of at least 1 radiofrequency ablation (RFA) application. Radiographic response was assessed at ≥10 weeks and ≥3 months using modified Response Evaluation Criteria in Solid Tumors: complete response (CR, 100% reduction), partial response (PR, 30–99%), and no response (NR, &lt;30%). Predictive factors were evaluated using logistic regression. Adverse events were classified per AGREE (Adverse events in GastrRointEstinal Endoscopy) criteria. This study was exempt from institutional review board review after assessment.</div></div><div><h3>RESULTS</h3><div>Among 46 patients (mean age, 60.9 years; 53% men), most tumors (93.6%) were well-differentiated grade 1, with a mean size of 12.7 mm. Technical success was 100%, with a mean of 2.9 RFA applications. At initial follow-up, CR was achieved in 32.6%, PR in 47.8%, and NR in 19.6%. Of patients with PR/NR (<em>n</em> = 31), 58.1% underwent repeat RFA. At final follow-up (mean, 15.7 months), cumulative response rates were as follows: CR, 60.0%; PR, 31.1%; and NR, 8.9%. Longer probe tips (odds ratio, 5.31; 95% CI, 1.10-33.87) and more RFA applications (odds ratio, 2.61; 95% CI, 1.19-3.9) predicted CR. Adverse events occurred in 15.2% (<em>n</em> = 7), including mild abdominal pain, mild pancreatitis, and 1 grade III bleed.</div></div><div><h3>CONCLUSION</h3><div>EUS-RFA for NF-PanNETs demonstrates high technical success, durable tumor response, and an acceptable safety profile. Probe length and application number may influence outcomes.</div></div>","PeriodicalId":36169,"journal":{"name":"Techniques and Innovations in Gastrointestinal Endoscopy","volume":"28 3","pages":"Article 250971"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Expert Consensus on Endoscopic Closure Devices and Techniques Using A Modified Delphi Process","authors":"Maham Hayat,&nbsp;Heiko Pohl,&nbsp;Thurarshen Jeyalingam,&nbsp;Mohamed Othman,&nbsp;Peter Draganov,&nbsp;Dennis Yang","doi":"10.1016/j.tige.2026.250986","DOIUrl":"10.1016/j.tige.2026.250986","url":null,"abstract":"<div><h3>BACKGROUND AND AIMS</h3><div>Effective endoscopic closure has become a critical need with advances in therapeutic endoscopy. Yet, clinical practice remains highly variable, due to the ever-growing number of devices and the lack of high-quality evidence. We aimed to establish a consensus on best-practice recommendations regarding endoscopic closure devices and techniques.</div></div><div><h3>METHODS</h3><div>A steering committee developed an initial questionnaire consisting of 4 domains (26 statements): general approach to endoscopic closure, technical suggestions on closure devices, prophylactic closure of postresection defects, and management of perforations. A total of 65 experts participated in the 2 rounds of the Delphi process, with quantitative and qualitative data analyzed for each round to achieve consensus.</div></div><div><h3>RESULTS</h3><div>A total of 22 statements achieved high degree of consensus. Overall, the expert panel agreed that the optimal technique for closure needs to be individualized based on several factors (endoscopist, device availability, patient and tissue characteristics) and may require a multimodal approach. Consensus was achieved on several technical tips on how to optimally utilize different closure devices (through-the-scope clips, tissue apposition clips, over-the-scope clips, and suturing). Routine prophylactic closure of postresection defects ≥15 mm in the duodenum and ≥20 mm in the right colon was recommended, but not in the stomach or left colon.</div></div><div><h3>CONCLUSION</h3><div>The results of this Delphi process established an international expert agreement on several key aspects regarding best practices on indications, device selection strategies, and technical considerations for endoscopic closure.</div></div>","PeriodicalId":36169,"journal":{"name":"Techniques and Innovations in Gastrointestinal Endoscopy","volume":"28 4","pages":"Article 250986"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148779336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cultivating Innovation: A Decade of Reflection on The Evolution of Techniques and Innovations in Gastrointestinal Endoscopy","authors":"Vinay Chandrasekhara","doi":"10.1016/j.tige.2026.250982","DOIUrl":"10.1016/j.tige.2026.250982","url":null,"abstract":"","PeriodicalId":36169,"journal":{"name":"Techniques and Innovations in Gastrointestinal Endoscopy","volume":"28 4","pages":"Article 250982"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148661287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Invisible Dysplasia Found on Random Biopsy Referred for Chromoendoscopy in a Community Practice","authors":"Suvithan Rajadurai ,&nbsp;Samir A. Shah","doi":"10.1016/j.tige.2025.250945","DOIUrl":"10.1016/j.tige.2025.250945","url":null,"abstract":"","PeriodicalId":36169,"journal":{"name":"Techniques and Innovations in Gastrointestinal Endoscopy","volume":"28 1","pages":"Article 250945"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145384187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous Endoscopic Vacuum Therapy for Patients With Postoperative Enterocutaneous Fistulas: A Retrospective Study","authors":"Marcus Kantowski ,&nbsp;Nathaniel Melling ,&nbsp;Thomas Roesch ,&nbsp;Chengcheng Christine Zhang","doi":"10.1016/j.tige.2025.250947","DOIUrl":"10.1016/j.tige.2025.250947","url":null,"abstract":"<div><h3>BACKGROUND AND AIMS</h3><div>Enterocutaneous fistulas following intestinal surgery are a feared complication with high morbidity and mortality. The therapeutic management of these fistulas is challenging. Percutaneous endoscopic vacuum therapy may be a new promising approach. Therefore, we aimed to evaluate the feasibility, effectiveness, and safety of percutaneous endoscopic vacuum therapy in patients with postoperative enterocutaneous fistulas.</div></div><div><h3>METHODS</h3><div>Patients with postoperative enterocutaneous fistulas treated with percutaneous endoscopic vacuum therapy were included and analyzed retrospectively. The primary endpoint was successful fistula closure using percutaneous endoscopic vacuum therapy.</div></div><div><h3>RESULTS</h3><div>This study included 44 patients, with a median follow-up of 5.9 months. Most patients (n = 35 of 44, 79.5%) received combined endoscopic treatments. The median duration of percutaneous endoscopic therapy was 37 days (range, 1-370 days), with a median of 6 endoscopic interventions (range, 1-15). Percutaneous endoscopic vacuum therapy was successful in 30 patients (68.2%). The remaining 14 patients (31.8%) required surgical revision, and of these, 10 (71.4%) achieved complete healing postoperatively. The overall success rate was 90.1% (n = 40 of 44). Procedure-related complications (anastomotic stenosis and duodenal ulcer bleeding) occurred in 6 patients (n = 6 of 44, 13.6%); 4 were treated endoscopically, while 2 required reoperation. The 30-day mortality rate was 20.5% (n = 9 of 44), and none of the deaths were treatment-related.</div></div><div><h3>CONCLUSIONS</h3><div>Percutaneous endoscopic vacuum therapy is feasible, effective, and safe for endoscopic treatment of postoperative enterocutaneous fistulas. Given the complexity of this severe condition, developing an individualized, multidisciplinary therapeutic concept based on clinical conditions and fistula morphology is crucial for the successful treatment.</div></div>","PeriodicalId":36169,"journal":{"name":"Techniques and Innovations in Gastrointestinal Endoscopy","volume":"28 1","pages":"Article 250947"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145384188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiobesity Medications and Endoscopic Bariatric Therapies: A Narrative Review","authors":"Luke Frankl,&nbsp;Leah Kim,&nbsp;Violeta Popov","doi":"10.1016/j.tige.2026.250976","DOIUrl":"10.1016/j.tige.2026.250976","url":null,"abstract":"<div><div>The global obesity epidemic requires effective weight-loss solutions. Endoscopic bariatric therapies (EBTs), such as endoscopic sleeve gastroplasty, transoral outlet reduction, and intragastric balloons, provide minimally invasive alternatives to traditional surgery, demonstrating efficacy in weight loss and metabolic improvement. However, some patients experience suboptimal weight loss and recurrent weight gain. The addition of pharmacotherapy, particularly incretin analogs such as liraglutide, semaglutide, and tirzepatide, has been explored to improve EBT outcomes. Studies suggest that combining EBTs with pharmacotherapy, particularly following endoscopic sleeve gastroplasty, improves total body weight loss, while evidence for an additive benefit of intragastric balloons and antiobesity medications remains mixed. Although combination therapies with transoral outlet reduction for recurrent weight gain after Roux-en-Y gastric bypass show promise, the optimal timing and pharmacotherapeutic options need further clarification. Future studies should focus on refining patient selection, timing of medication initiation, and cost-effectiveness to maximize the benefits of combined treatments for managing obesity.</div></div>","PeriodicalId":36169,"journal":{"name":"Techniques and Innovations in Gastrointestinal Endoscopy","volume":"28 3","pages":"Article 250976"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148565366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}